This article is more than 5 years old. Information may no longer be current.
Intracameral injection after shunt implantation yields no safety signals
Click Here to Manage Email Alerts
SAN DIEGO — No safety concerns were identified after intracameral injection of a steroid, NSAID and antibiotic combination in glaucoma patients undergoing cataract surgery with implantation of a supraciliary shunt, according to a speaker.
At the American Society of Cataract and Refractive Surgery meeting, David Stephens, MD, discussed a study conducted in 48 eyes of 31 patients who underwent cataract surgery and placement of the Alcon CyPass shunt. Each patient received an intracameral injection of DMK (dexamethasone, moxifloxacin and ketorolac, Imprimis) at the end of the procedure.
At 3 months, glaucoma medications were reduced from 1.31 to 0.27, and mean IOP decreased from 19.7 mm Hg to 12.93 mm Hg, a decrease of 6.77 mm Hg.
“This is similar to the COMPASS study, which showed a decrease of 7 mm Hg; however, our starting IOP was slightly lower than in the COMPASS study,” Stephens said.
The study showed no instances of pressure spikes of 15 mm Hg or more, endophthalmitis, severe inflammation, cystoid macular edema, retinal detachments or hypotony, he said.
“Our study indicates that intracameral steroid, NSAID and antibiotic should be considered safe in glaucoma eyes having cataract surgery with supraciliary shunt implantation,” Stephens said. - by Rebecca L. Forand
Reference:
Stephens D. Safety and efficacy of intracameral injection of steroid, antibiotic and NSAID in the setting of cataract surgery and supraciliary shunt. Presented at American Society of Cataract and Refractive Surgery annual meeting; May 3-7, 2019; San Diego.
Disclosure: Stephens reports no relevant financial disclosures.